BIOMAT Database Logo BIOMAT Database Logo

Partial purification and properties of a plasma ouabain-like inhibitor of Na+, K+-ATPase in patients with essential hypertension. 1988

F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Department of Medicine and Geriatrics, Osaka University Medical School, Japan.

Plasma levels of an ouabain-like inhibitor of Na+,K+-ATPase were higher in patients with essential hypertension compared with normal levels. The ouabain-like inhibitor was correlated significantly with blood pressure and was increased by a high-salt diet. The substance was partially purified by high performance liquid chromatography which revealed lipid-like properties, but the elution time was different from that of free unsaturated fatty acid on silica-gel high performance liquid chromatography. Its molecular weight was 600 or less, as estimated by high performance liquid chromatography with an HSG-15H column. The ouabain-like substance inhibited Na+, K+-ATPase in competition with KCl and showed positive ouabain-like immunoreactivity, whereas lysophosphatidylcholine was a non-competitive inhibitor. The ouabain-like substance was unstable at room temperature and decomposed to smaller molecular compounds which did not inhibit Na+, K+-ATPase. The inhibitory fraction gave a positive thiobarbituric acid reaction test. The mobility of the ouabain-like inhibitor on silica-gel thin-layer chromatography was different from that of prostaglandins and arachidonic acid. These results indicate that the plasma ouabain-like inhibitor of patients with essential hypertension is a lipid which is different from free fatty acid or lysophosphatidylcholine, and may be an unstable peroxide.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D002298 Cardenolides C(23)-steroids with methyl groups at C-10 and C-13 and a five-membered lactone at C-17. They are aglycone constituents of CARDIAC GLYCOSIDES and must have at least one double bond in the molecule. The class includes cardadienolides and cardatrienolides. Members include DIGITOXIN and DIGOXIN and their derivatives and the STROPHANTHINS. Cardenolide
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000254 Sodium-Potassium-Exchanging ATPase An enzyme that catalyzes the active transport system of sodium and potassium ions across the cell wall. Sodium and potassium ions are closely coupled with membrane ATPase which undergoes phosphorylation and dephosphorylation, thereby providing energy for transport of these ions against concentration gradients. ATPase, Sodium, Potassium,Adenosinetriphosphatase, Sodium, Potassium,Na(+)-K(+)-Exchanging ATPase,Na(+)-K(+)-Transporting ATPase,Potassium Pump,Sodium Pump,Sodium, Potassium ATPase,Sodium, Potassium Adenosinetriphosphatase,Sodium-Potassium Pump,Adenosine Triphosphatase, Sodium, Potassium,Na(+) K(+)-Transporting ATPase,Sodium, Potassium Adenosine Triphosphatase,ATPase Sodium, Potassium,ATPase, Sodium-Potassium-Exchanging,Adenosinetriphosphatase Sodium, Potassium,Pump, Potassium,Pump, Sodium,Pump, Sodium-Potassium,Sodium Potassium Exchanging ATPase,Sodium Potassium Pump
D012503 Saponins A type of glycoside widely distributed in plants. Each consists of a sapogenin as the aglycone moiety, and a sugar. The sapogenin may be a steroid or a triterpene and the sugar may be glucose, galactose, a pentose, or a methylpentose. Saponin

Related Publications

F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
A circulating inhibitor of (Na+ + K+)ATPase associated with essential hypertension.
December 1982, Nature,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Evidence for a Na-K-ATPase-inhibitor in erythrocytes of patients with essential hypertension.
August 1985, European journal of clinical investigation,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Predominance of high molecular weight plasma Na(+)-K(+)-ATPase inhibitor in essential hypertension.
August 1993, American journal of hypertension,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Differential properties between an endogenous brain Na+, K(+)-ATPase inhibitor and ouabain.
April 1997, Neurochemical research,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Ouabain-like Na+,K(+)-ATPase inhibitory activity of a plasma extract in normal pregnancy and pregnancy induced hypertension.
December 1991, Japanese journal of pharmacology,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Purification of a Na+/K+ ATPase inhibitor from borderline hypertensives' plasma.
June 1990, Biochemical and biophysical research communications,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Some properties of erythrocyte Na+-K+-ATPase in essential hypertension.
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Partial purification and properties of (Na+ + K+)-ATPase from Potamon potamios.
January 1991, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Partial purification and properties of the inhibitors of Na, K-ATPase and ouabain-binding in bovine central nervous system.
March 1984, Journal of neurochemistry,
F Masugi, and T Ogihara, and K Sakaguchi, and A Tomii, and T Hasegawa, and Y Chen, and M Azuma, and Y Kumahara
Raised concentration of a circulating Na+-K+-ATPase inhibitor in essential hypertension.
January 1982, Contributions to nephrology,
Copied contents to your clipboard!